Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.73 |
| ▸ | CA1 | P00915 | 4/20 | 0.73 |
| ▸ | CA2 | P00918 | 4/20 | 0.73 |
| ▸ | CA9 | Q16790 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | NSD2 | O96028 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51033 | 1.00 | CA12 (0.73) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1055674 | 1.00 | CA12 (0.73) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1055673 | 0.98 | CA12 (0.71) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1055670 | 0.98 | CA12 (0.71) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL69006 | 0.86 | CA12 (0.76) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL10423505 | 0.86 | ALDH1A1 (0.60) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL31080938 | 0.86 | CA12 (0.76) | CA12CA1CA2CA9ALDH1A1 | |
| Questiomycin B SCHEMBL1366115 | 0.86 | CA9 (0.60) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1959737 | 0.85 | CA2 (1.00) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL31093944 | 0.84 | HPGD (0.68) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103640-A1 | NEW METHOD OF SYNTHESIS OF CHITOSAN DERIVATIVES AND USES THEREOF | Novochizol SA (CH) | 2022-12-21 | — | — | EP | claimed |
| EP-3220940-B1 | COMPOSITIONS AND METHODS FOR MODULATING AT2R ACTIVITY | NOVOPYXIS INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-11059907-B2 | Antibodies that bind Notum Pectinacetylesterase | LEXICON PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10675324-B2 | Compositions and methods for modulating AT2R activity | NOVOPYXIS INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190241677-A1 | ANTIBODIES THAT BIND NOTUM PECTINACETYLESTERASE | LEXICON PHARMACEUTICALS, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190000916-A1 | COMPOSITIONS AND METHODS FOR MODULATING AT2R ACTIVITY | NOVOPYXIS INC. (US) | 2019-01-03 | — | — | US | disclosed |
| EP-2643019-B1 | ANTIBODIES TO NOTUM PECTINACETYLESTERASE | LEXICON PHARMACEUTICALS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10105411-B2 | Compositions and methods for modulating AT2R activity | NOVOPYXIS INC. (US) | 2018-10-23 | — | — | US | disclosed |
| EP-2877487-B1 | MODIFIED FACTOR X POLYPEPTIDES AND USES THEREOF | CATALYST BIOSCIENCES INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9856467-B2 | Modified factor X polypeptides and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-5252603-A | Immunosuppressive analogues and derivatives of succinylacetone | CETUS CORPORATION (US) | 1993-10-12 | — | — | US | disclosed |
| US-5216005-A | Treating autoimmune diseases, organ tissue transplants | CETUS CORPORATION (US) | 1993-06-01 | — | — | US | disclosed |
| US-5173482-A | A dioxoalkyl phosponate or a proline-modified polyoxyethylene glycol derivative; autoimmune diseases; organ transplants; immunoassay | CETUS CORPORATION (US) | 1992-12-22 | — | — | US | disclosed |
| EP-0305409-B1 | SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS USING POLYPROLINE CONJUGATION | CETUS ONCOLOGY CORPORATION (US) | 1991-10-30 | — | — | EP | disclosed |
| EP-0423980-A1 | Stem cell factor | AMGEN INC. (US) | 1991-04-24 | — | — | EP | disclosed |
| US-4895872-A | TREATING HYPERACTIVE IMMUNE SYSTEMS; AUTOIMMUNE AND GRAFT/HOST DISEASES | CETUS CORPORATION (US) | 1990-01-23 | — | — | US | disclosed |
| US-4894226-A | SPACERS, CROSSLINKING | CETUS CORPORATION (US) | 1990-01-16 | — | — | US | disclosed |
| WO-1990000049-A2 | IMMUNOSUPPRESSIVE ANALOGUES AND DERIVATIVES OF SUCCINYLACETONE | CETUS CORPORATION (US) | 1990-01-11 | — | — | WO | disclosed |
| EP-0305409-A1 | SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS USING POLYPROLINE CONJUGATION. | CETUS CORP (US) | 1989-03-08 | — | — | EP | disclosed |
| WO-1988003412-A1 | SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS USING POLYPROLINE CONJUGATION | CETUS CORPORATION (US) | 1988-05-19 | — | — | WO | disclosed |